Randomized Trial in Adult Participants With Acute Migraines
Double-Blind, Randomized, Placebo-controlled, Safety and Efficacy Trial of BHV-3500 (Zavegepant) Intranasal for the Acute Treatment of Migraine
2 other identifiers
interventional
1,978
1 country
94
Brief Summary
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Oct 2020
Shorter than P25 for phase_3
94 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 11, 2020
CompletedFirst Posted
Study publicly available on registry
September 30, 2020
CompletedStudy Start
First participant enrolled
October 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 10, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 22, 2021
CompletedResults Posted
Study results publicly available
March 16, 2023
CompletedApril 24, 2023
April 1, 2023
12 months
September 11, 2020
February 17, 2023
April 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.
2 hours post-dose
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
MBS was reported as nausea, photophobia, or phonophobia immediately before dosing using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.
2 hours post-dose
Secondary Outcomes (17)
Percentage of Participants With Pain Relief at 2 Hours Post-dose
2 hours post-dose
Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose
2 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose
From 2 to 24 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose
From 2 to 48 hours post-dose
Percentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose
From 2 to 24 hours post-dose
- +12 more secondary outcomes
Study Arms (2)
Zavegepant
EXPERIMENTALParticipants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar Unidose System (UDS) liquid spray device.
Placebo
PLACEBO COMPARATORParticipants administered a single intranasal dose of zavegepant matching placebo on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar UDS liquid spray device.
Interventions
Eligibility Criteria
You may qualify if:
- Participant has at least 1-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, including the following:
- Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age
- Migraine attacks, on average, lasting about 4-72 hours if untreated
- Not more than 8 attacks of moderate to severe intensity per month within the last 3 months
- At least 2 consistent migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening period
- Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period.
- Participants on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change during the course of the study.
- Participants with contraindications for use of triptans may be included provided they meet all other study entry criteria.
- Male and Female participants ≥18 years of age.
You may not qualify if:
- Participant with a history of HIV disease
- Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.
- Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however participants can be included who have stable hypertension and/or diabetes for at least 3 months prior to being enrolled).
- Participants with major depressive episode within the last 12 months, major depressive disorder or any anxiety disorder requiring more than 1 medication for each disorder.
- History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or participants who have met DSM-V criteria for any significant substance use disorder within the past 12 months.
- History of nasal surgery in the 6 months.
- Evidence at screening of significant nasal conditions that may affect the administration or absorption of the nasal product (e.g. severe septum deviation, nasal deformity or blockage, inflammation, perforation, mucosal erosion or ulceration, polyposis, nasal trauma)
- Participation in any other investigational clinical trial while participating in this clinical trial. Participation in a COVID-19 mRNA vaccine study (vaccine must be authorized under FDA emergency use authorization or approval) who are at least 30 days post last dose of the vaccine are permitted to be screened for this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (94)
Medical Affiliated Research Center
Huntsville, Alabama, 35801, United States
Coastal Clinical Research, LLC, An AMR Co.
Mobile, Alabama, 36608, United States
MD First Research
Chandler, Arizona, 85286, United States
Tucson Neuroscience Research
Tucson, Arizona, 85710, United States
Baptist Health Center for Clinical Research
Little Rock, Arkansas, 72205, United States
Axiom Research, LLC
Colton, California, 92324, United States
Pharmacology Research Institute
Encino, California, 91316, United States
eStudySite
La Mesa, California, 91942, United States
Synergy San Diego
Lemon Grove, California, 91945, United States
Collaborative Neuroscience Network, LLC
Long Beach, California, 90806, United States
Pharmacology Research Institute
Los Alamitos, California, 90720, United States
Clinical Research Institute
Los Angeles, California, 90404, United States
Wr-Pri, Llc
Newport Beach, California, 92660, United States
Artemis Institute for Clinical Research
Riverside, California, 92503, United States
Artemis Institute for Clinical Research
San Diego, California, 92103, United States
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California, 91403, United States
CT Clinical Research
Cromwell, Connecticut, 06416, United States
Ki Health Partners, LLC dba New England Institute for Clinical Research
Stamford, Connecticut, 06095, United States
Neurology Offices of South Florida
Boca Raton, Florida, 33428, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, 32256, United States
Multi-Specialty Research Associates, Inc.
Lake City, Florida, 32055, United States
Meridien Research
Lake Mary, Florida, 32746, United States
AppleMed Research Group, LLC
Miami, Florida, 33155, United States
The Neurology Research Group
Miami, Florida, 33176, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32801, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32819, United States
Complete Health Research
Ormond Beach, Florida, 32174, United States
Ideal Clinical Research
Pembroke Pines, Florida, 33026, United States
Clinical Research Center of Florida
Pompano Beach, Florida, 33060, United States
Clin-Med Research & Development, LLC
South Miami, Florida, 33143, United States
ForCare Clinical Research
Tampa, Florida, 33613, United States
JSV Clinical Research Study, Inc.
Tampa, Florida, 33634, United States
iResearch Atlanta, LLC
Decatur, Georgia, 30030, United States
Meridian Clinical Research, LLC
Savannah, Georgia, 31406, United States
Northwest Clinical Trials Inc.
Boise, Idaho, 83704, United States
Cedar Crosse Research Center
Chicago, Illinois, 60607, United States
Healthcare Research Network II, LLC
Flossmoor, Illinois, 60422, United States
Fort Wayne Neurological Center
Fort Wayne, Indiana, 46804, United States
Collective Medical Research
Prairie Village, Kansas, 66208, United States
Alliance for Multispecialty Research, LLC
Wichita, Kansas, 67205, United States
L-MARC Research Center
Louisville, Kentucky, 40213, United States
Crescent City Headache and Neurology Center
Chalmette, Louisiana, 70043, United States
DelRicht Research
New Orleans, Louisiana, 70124, United States
Boston Clinical Trials
Boston, Massachusetts, 02131, United States
Community Clinical Research Network
Marlborough, Massachusetts, 01752, United States
Boston Neuro Research Center
South Dartmouth, Massachusetts, 02747, United States
Medvadis Research Corporation
Waltham, Massachusetts, 02451, United States
Michigan Headache and Neurological Institute
Ann Arbor, Michigan, 48104, United States
Clinical Research Institute, Inc.
Minneapolis, Minnesota, 55402, United States
StudyMetrix Research
City of Saint Peters, Missouri, 63303, United States
Healthcare Research Network
Hazelwood, Missouri, 63042, United States
Clinvest Research LLC
Springfield, Missouri, 65810, United States
Sundance Clinical Research, LLC
St Louis, Missouri, 63141, United States
Excel Clinical Research
Las Vegas, Nevada, 89109, United States
Center for Emotional Fitness
Cherry Hill, New Jersey, 08002, United States
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico, 87102, United States
Dent Neurosciences Research Center
Amherst, New York, 14226, United States
Regional Clinical Research
Endwell, New York, 13760, United States
Central New York Clinical Research
Manlius, New York, 13104, United States
Fieve Clinical Research, Inc
New York, New York, 10017, United States
Rochester Clinical Research, Inc.
Rochester, New York, 14609, United States
Montefiore Medical Center: Headache Center
The Bronx, New York, 10461, United States
Headache Wellness Center
Greensboro, North Carolina, 27405, United States
PharmQuest LLC
Greensboro, North Carolina, 27408, United States
PMG of Raleigh, LLC
Raleigh, North Carolina, 27609, United States
Wilmington Health, PLLC
Wilmington, North Carolina, 28401, United States
Hometown Urgent Care & Research/ Wellnow
Cincinnati, Ohio, 45215, United States
Hometown Urgent Care and Research
Columbus, Ohio, 43214, United States
Hometown Urgent Care and Research
Dayton, Ohio, 45424, United States
The Orthopedic Foundation
New Albany, Ohio, 43054, United States
OK Clinical Research LLC
Edmond, Oklahoma, 73034, United States
Tekton Research, Inc.
Yukon, Oklahoma, 73099, United States
Summit Research Network
Portland, Oregon, 97210, United States
Clinical Research of Philadelphia, LLC
Philadelphia, Pennsylvania, 19114, United States
Preferred Primary Care Physicians, Inc.
Pittsburgh, Pennsylvania, 15236, United States
Preferred Primary Care Physicians, Inc.
Union, Pennsylvania, 15401, United States
MD First Research
Lancaster, South Carolina, 29720, United States
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, 29464, United States
Volunteer Research Group
Knoxville, Tennessee, 37920, United States
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119, United States
FutureSearch Trials of Neurology
Austin, Texas, 78731, United States
Donald J. Garcia, Jr, MD, PA
Austin, Texas, 78737, United States
FutureSearch Trials of Dallas, LP
Dallas, Texas, 75231, United States
Red Star Research LLC
Lake Jackson, Texas, 77566, United States
Clinical Trials of Texas, Inc. (CTT)
San Antonio, Texas, 78229, United States
DM Clinical Research
Tomball, Texas, 77375, United States
Alpine Medical Group
Salt Lake City, Utah, 84107, United States
J. Lewis Research, Inc. / Jordan River Family Medicine
South Jordan, Utah, 84095, United States
Charlottesville Medical Research Center, LLC
Charlottesville, Virginia, 22911, United States
Health Research of Hampton Roads, Inc.
Newport News, Virginia, 23606, United States
Tidewater Integrated Medical Research
Virginia Beach, Virginia, 23454, United States
Northwest Clinical Research Center
Bellevue, Washington, 98007, United States
Seattle Women's: Health, Research, Gynecology
Seattle, Washington, 98105, United States
Clinical Investigation Specialist, Inc.
Kenosha, Wisconsin, 53144, United States
Related Publications (1)
Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023 Mar;22(3):209-217. doi: 10.1016/S1474-4422(22)00517-8.
PMID: 36804093DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Chief Medical Officer
- Organization
- Biohaven Pharmaceuticals, Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Masking Details
- Double-blind to Sponsor, Investigator and Participant.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 11, 2020
First Posted
September 30, 2020
Study Start
October 27, 2020
Primary Completion
October 10, 2021
Study Completion
October 22, 2021
Last Updated
April 24, 2023
Results First Posted
March 16, 2023
Record last verified: 2023-04